Pediarix®

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Haemophilus Influenzae Type bInfections, MeningococcalNeisseria Meningitidis

Phase 3

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

CompletedNCT00614614

GlaxoSmithKlineInfections, Meningococcal

Start: 2008-02-13End: 2009-09-17Updated: 2018-09-21

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

CompletedNCT01978093

GlaxoSmithKlineHaemophilus Influenzae Type b, Neisseria Meningitidis

Start: 2014-02-01End: 2016-03-18Updated: 2018-09-14

Related Papers

Immunogenicity and safety of the <i>Haemophilus influenzae</i> type b and <i>Neisseria meningitidis</i> serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants

Human Vaccines & Immunotherapeutics2018-09-254 citations

Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae–N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy

Vaccine2014-08-2213 citations